Vaxart, Inc.
Vaxart, Inc. (VXRT): 12 pipeline candidates · ~119 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
119.3 months
D/E 0.91 · 0% dilution
Lead: Phase 2
12 candidates
N/A
1 buy · 0 sells (180d)
A transparent, data-derived signal for Vaxart, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$138.0M
Cash
$50.7M
Quarterly Burn
$2.1M
Runway
119.3 mo
Revenue
$39.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| bivalent norovirus vaccine candidate | Phase 2 |
| comirnaty | Phase 2 |
| investigational oral vaccine candidate for covid-19 | Phase 2 |
| norovirus gi.1 norwalk virus inoculum | Phase 1/Phase 2 |
| seasonal influenza vaccine candidate | Phase 2 |
| vxa g1.1 nn-t | Phase 1 |
| vxa g2.4 ns-t | Phase 1 |
| vxa-cov2-1.1-s | Phase 2 |
| vxa-cov2-3.1 | Phase 2 |
| vxa-cov2-3.3 | Phase 2 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$15
| Holder | Shares | Value |
|---|---|---|
| lvm capital management ltd/mi | 25,000 | $15 |
Frequently asked questions
How many drug candidates are in Vaxart, Inc.'s pipeline?
Vaxart, Inc. (VXRT) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Vaxart, Inc.'s lead drug candidate?
Vaxart, Inc.'s most advanced tracked candidate is bivalent norovirus vaccine candidate (Phase 2) for Norovirus Infections.
What is Vaxart, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Vaxart, Inc. has approximately 119.3 months of cash runway.
What is Vaxart, Inc.'s market capitalization?
Vaxart, Inc.'s market capitalization is approximately $138.0M.
Who is the CEO of Vaxart, Inc.?
Mr. Steven Lo is the chief executive officer of Vaxart, Inc. (VXRT).
Get the full picture on Vaxart, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.